Soon to be merged CMO DSM Pharmaceutical Products (DPP) has been contracted to provide process development for a protein allergy drug being developed by Tunitas Therapeutics.
Royal DSM wants to merge its pharmaceutical products business with Patheon and has signed a deal with the latter's owner, investment group JLL Partners.
Chiltern has a new Director of Global Pharmacovigilance and there's an appointment at DSM in this week's lowdown on the outsourcing industry's movers and shakers.
DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.
Royal DSM NV says its pharmaceutical contract manufacturing business model is ‘out of step with market needs’ after the unit’s Q1 performance blots an otherwise positive set of financials.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has announced the launch of InnoSyn route scouting services, meeting pharma needs to outsource process development R&D.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
